Intravitreal aflibercept has been used in the UK for treatment of a variety of retinal vascular disorders and from April 2020 has had market authorisation for use in a pre-filled syringe (PFS).

We report a series of five eyes in four patients who developed transient CRAO immediately post injection using the PFS (see Table 1). These occurred shortly after the adoption of the PFS in our departments. All patients had previously received intravitreal injections (ranibizumab or aflibercept) without complication.

Table 1 Case series of patients developing transient CRAO after intravitreal injection with a pre-filled aflibercept syringe.
Full size table

Log in or create a free account to read this content

Gain free access to this article, as well as selected content from this journal and more on nature.com

Access through your institution

or

Sign in or create an account
Continue with Google
Continue with ORCiD